These temporal variations highlight the necessity of prioritizing intestinal inflammation markers (Fc, CRP) during early treatment monitoring and focusing on anemia (Hb) and chronic inflammation (ESR) in long-term management, thereby providing a robust foundation for a staged clinical strategy in CD. This evidence concerns the gene GSTM1 and anemia (phenotype).